Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Science 12 August 2005:
Vol. 309. no. 5737, p. 1003
DOI: 10.1126/science.309.5737.1003
Prev | Table of Contents | Next

News Focus

HIV/AIDS:
Hedged Bet: An Unusual AIDS Vaccine Trial

Jon Cohen

No one has yet found an AIDS vaccine that can trigger effective antibodies against HIV's surface protein. So Merck has constructed a vaccine that abandons antibodies altogether, and the company is testing it in a fast-tracked study to determine whether it's worth pursuing the approach.

Read the Full Text


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Adenoviral vectors persist in vivo and maintain activated CD8+ T cells: implications for their use as vaccines.
N. Tatsis, J. C. Fitzgerald, A. Reyes-Sandoval, K. C. Harris-McCoy, S. E. Hensley, D. Zhou, S.-W. Lin, A. Bian, Z. Q. Xiang, A. Iparraguirre, et al. (2007)
Blood 110, 1916-1923
   Abstract »    Full Text »    PDF »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)